PharmaFocus Today – media

CanSino Biologics’ Td5cp for adolescents and adults has been included in the priority review process, accelerating its deployment of DPT protection throughout the entire life cycle.

May 11, 2026 – CanSino Biologics Inc. (hereinafter referred to as “ CanSino Biologics ” , 688185.SH , 06185.HK ) announced that its independently developed adsorbed acellular diphtheria-tetanus-diphtheria-tetanus combined vaccine ( for individuals aged 6 years and older) (hereinafter referred to as “ Td5cp for adolescents and adults ” ) has been officially included in the priority review list by the National Medical Products Administration ( NMPA ). With the accelerated review and approval process, this product, as an important part of the company’s comprehensive DPT protection system throughout the entire life cycle, is expected to fill the gap in DPT booster immunization products for individuals aged 6 years and older in China, helping to build a broader and stronger immune barrier. Pertussis is an acute respiratory infectious disease caused by Bordetella pertussis, and it is highly contagious . <sup> 1 </sup> In recent years, pertussis has shown a resurgence ...
- Source: drugdu
- 34
- May 12, 2026
Industry News | Harbour BioMed Announces FDA Approval of HBM7004 for the Treatment of Advanced Solid Tumors

Harbour BioMed (“the Company”; HKEX code 02142), a global biopharmaceutical company dedicated to the discovery and development of novel antibody therapeutics in the fields of immunology, oncology, and other diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for HBM7004, thereby initiating a first-in-human (FIH) Phase I clinical trial. This study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of HBM7004 in subjects with advanced solid tumors. HBM7004 is a novel B7H4xCD3 bispecific antibody developed using the company’s HBICE® platform . This bispecific antibody is designed to provide a differentiated approach to cancer immunotherapy, potentially improving efficacy and safety. The development of HBM7004 further demonstrates the versatility and plug-and-play advantages of the HBICE® platform . In preclinical studies, HBM7004 exhibited a tumor-dependent B7H4-dependent T-cell activation pathway. In multiple animal models, HBM7004 demonstrated strong antitumor efficacy, significant in vivo stability, ...
- Source: drugdu
- 34
- May 12, 2026
The world’s first! GSK’s blockbuster hepatitis B drug licensed to Chia Tai Tianqing Pharmaceutical Group.

China Biopharmaceutical has acquired the world’s first blockbuster drug with the potential to achieve a functional cure for hepatitis B in the fastest possible time. On May 11, China Biopharmaceutical (01177.HK) officially announced that its core subsidiary, Chia Tai Tianqing Pharmaceutical Group, has entered into an exclusive strategic collaboration with multinational pharmaceutical company GlaxoSmithKline (LSE/NYSE: GSK) to accelerate the latter’s first-in-class innovative drug for chronic hepatitis B , Bepirovirsen (code name: GSK836), in China. This promising drug, which is highly anticipated by the industry, has received “breakthrough therapy” designation in China and has been included in the priority review and approval process. Its launch will bring a revolutionary breakthrough to the treatment of hepatitis B in China. Under the terms of the agreement, Chia Tai Tianqing Pharmaceutical Group will be responsible for the import, distribution, hospital access, and promotional and non-promotional activities of bepirovirsen in mainland China. All sales revenue ...
- Source: drugdu
- 31
- May 12, 2026
The Two Sides of RMC-6236

Following Revolution’s announcement on April 13th of positive results from the Phase III clinical trial RASolute302 of its pan-RAS inhibitor RMC-6236 in previously treated metastatic pancreatic cancer patients, the drug has now announced the latest research progress in first-line treatment. In terms of efficacy, RMC-6236 continues to surprise the market, demonstrating impressive remission rates whether used as a monotherapy or in combination therapy, and bringing new expectations to the industry. However, the potential toxicity of RMC-6236 continues to emerge. In particular, in the RMC-GI-102 study of first-line combination chemotherapy, grade ≥3 adverse reactions accounted for as high as 73%. Currently, the impact of this safety hazard on the subsequent R&D layout of RMC-6236 is still unclear, but it has pointed out a clear direction for differentiated breakthroughs for subsequent competitors in the same field. 01 The Two Sides of RMC-6236 RMC-6236 is a two-sided unit. In terms of efficacy, it ...
- Source: drugdu
- 31
- May 12, 2026
A rare disease company was acquired for $4.1 billion.

Italian pharmaceutical company Angelini Pharma recently announced its acquisition of Catalyst, a US-based rare disease specialist, for $4.1 billion, aiming to capitalize on the lucrative US market. The two companies expect to close the deal in the third quarter. According to publicly available information, Catalyst was founded in 2002 and went public on NASDAQ in 2006. The company is patient-centric, focusing on the introduction, development, and commercialization of novel medicines for rare and intractable diseases. In 2025, Catalyst’s revenue reached $589 million, a 20% increase, and this year’s revenue is projected to be between $615 million and $645 million. It has three products already on the market: Firdapse (amifampridine) is the company’s flagship product. It is the only evidence-based treatment approved by the FDA for Lambert-Eaton myasthenic syndrome (LEMS) in patients aged 6 and older. Sales of this drug are projected to reach $358 million in 2025, a 17% year-on-year ...
- Source: drugdu
- 33
- May 12, 2026
Revenue Soars 34% — Why BeiGene Decisively Cut 6 Pipeline Programs?

On May 8, BeiGene officially released its Q1 2026 financial results. Against the backdrop of overall pressure on China’s innovative drug industry and increasingly intense competition in R&D and commercialization, the company’s revenue performance bucked the trend and exceeded market expectations. Even more striking and industry-shaking, the company simultaneously announced a major pipeline strategy adjustment — terminating six investigational programs at once, covering five hot oncology targets and one autoimmune disease pipeline, signaling a clear strategic retrenchment. This “amputation-style” strategic adjustment marks the official end of China’s innovative drug leader’s past “land-grab” expansion model, fully transitioning to a new stage of high-quality development centered on “precision focus, efficient investment, and quality first,” setting a benchmark for industry transformation. I. Core Products Continue to Drive Growth, Commercialization Capabilities Re-validated Key financial data shows that in Q1 2026, BeiGene’s global product revenue reached US$1.5 billion, a substantial 34% year-over-year increase, demonstrating strong ...
- Source: drugdu
- 48
- May 11, 2026
InxMed Bio Partners with Fosun Pharma — Deal Worth RMB 1.115 Billion

On May 8, 2026, InxMed Biotechnology (Nanjing) Co., Ltd. announced a strategic partnership with Fosun Pharma. Under the agreement, InxMed Bio will grant Fosun Pharma the exclusive rights for sales, promotion, and full-channel commercialization of its two self-developed innovative FAK inhibitors, IN10018 (Ifebemtinib) and IN10028, in mainland China (excluding Hong Kong, Macau, and Taiwan). As consideration, InxMed Bio will receive an upfront payment of RMB 100 million, plus milestone payments of up to RMB 1.015 billion tied to R&D registration and sales performance. As consideration, InxMed Bio will receive an upfront payment of RMB 100 million, plus milestone payments of up to RMB 1.015 billion tied to R&D registration and sales performance. IN10018 is an innovative small-molecule FAK inhibitor with dual regulatory functions — kinase catalytic and protein scaffold — that exerts anti-tumor effects through multiple mechanisms including oncogenic pathway modulation and inhibition of tumor proliferation and invasion. The product ...
- Source: drugdu
- 49
- May 11, 2026
China Biopharmaceutical’s world-first innovative breast cancer treatment drug approved for first-line treatment indication

On May 6, Cumoxicillin Capsules (Saitanxin®), the world’s first CDK2/4/6 inhibitor independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a subsidiary of China Biopharmaceutical (01177.HK), received approval from the National Medical Products Administration (NMPA) for its combination with fulvestrant for the initial treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This is the second indication approved for the marketing of Cumoxicillin Capsules, providing a new treatment option for first-line treatment of HR-positive advanced breast cancer patients in China. Last December, cumoxicillin was approved in combination with fulvestrant for the treatment of HR+/HER2- breast cancer patients whose disease has progressed after prior endocrine therapy, and it is estimated that it has already benefited thousands of breast cancer patients in clinical practice. This new approval is primarily based on the CULMINATE-2 clinical trial, which showed that cumoxicillin in ...
- Source: drugdu
- 75
- May 9, 2026
The Phase III monotherapy clinical trial of Lianhuan Pharmaceutical’s LH-1801 tablets has been unblinded.

On the evening of May 7th, Lianhuan Pharmaceutical…(600513) issued an announcement stating that the Phase III monotherapy clinical trial of the Class 1 new drug LH-1801 tablets organized by the company has been unblinded and preliminary analysis results of the main data have been obtained recently. The announcement indicates that LH-1801 tablets are a novel SGLT-2 inhibitor, developed by Lianhuan Pharmaceutical in collaboration with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and possessing independent intellectual property rights in China.A new antidiabetic drug, indicated for type 2 diabetes. https://finance.eastmoney.com/a/202605073730257969.html
- Source: drugdu
- 65
- May 9, 2026
Shian Biotech and GSK reach licensing collaboration worth over $1 billion on oligonucleotide drugs

Recently , GlaxoSmithKline (GSK) and SiranBio (hereinafter referred to as “SiranBio”) reached a global exclusive licensing agreement for the investigational small interfering RNA (siRNA) oligonucleotide SA030. GSK will pay Shian Biotech an upfront payment and up to US$1.005 billion in development, registration and commercialization milestone payments, as well as tiered royalties based on global net sales (excluding mainland China, Hong Kong, Macau and Taiwan). SA030 is currently in Phase I clinical trials and targets activin receptor-like kinase 7 (ALK7) for the treatment of metabolic and cardiovascular diseases. Its design target avoids the weight loss market and targets the most difficult-to-treat abdominal visceral fat. According to International Pharmaceutical Business News, this is the second time in nearly six months that GSK has acquired siRNA assets from a Chinese biotechnology company. In the previous transaction, GSK acquired two siRNA drug candidates for respiratory, immune and inflammation (RI&I) fields from Frontier Biotechnologies for ...
- Source: drugdu
- 59
- May 9, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.